Loading clinical trials...

A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population

Clinical Characteristics and Real-World Outcomes of Chinese Patients With Hypertrophic Cardiomyopathy: A Prospective Cohort Study

NCT06775665•Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Willing and able to provide written informed consent (ICF) and any required privacy authorization before the start of the study.
•2. Aged ≥18 years at the time of signing the written informed consent.
•3. Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:
•1. Left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (MRI).
•2. Left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family.
•3. Exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening.

Exclusion Criteria

•1. Uncontrolled primary hypertension.
•2. Moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation.
•3. Confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., Fabry disease, amyloidosis).
•4. Expected life expectancy \<1 years.
•5. Severe infections, liver failure, renal failure, or other life-threatening conditions.

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, China

Key Dates

Start Date

June 1, 2026

Primary Completion Date

January 1, 2031

Completion Date

June 1, 2032

Last Updated

May 30, 2025

Enrollment

3,000

ESTIMATED participants

Conditions

Hypertrophic Cardiomyopathy (HCM)

Interventions

No interventions were applied to the patients.

OTHER

Contacts

Jianqiang Song, MD

CONTACT

+86 15267083207 22318324@zju.edu.cn

Shitian Guo, MD

CONTACT

+86 571-87784700 22218352@zju.edu.cn

HCMR Re-Imaging Study

NCT07054073

Hypertrophic Cardiomyopathy (HCM)

View study

RECRUITING

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

NCT07344480

Hypertrophic Cardiomyopathy (HCM)Heart Failure+1 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population

Inclusion Criteria

Exclusion Criteria

HCMR Re-Imaging Study

Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)

Multimodal Analysis of Endomyocardial Biopsies

The Application of T1 Mapping in Real-World

AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy

One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance